Once the devastating outbreak in India recedes, we also need the Serum Institute of India to get back on track and catch up on its delivery commitments to COVAX, Ghebreyesus said.
Read Also: World is at risk of 'vaccine apartheid', says WHO chief Tedros Adhanom
The UN children's agency UNICEF said the devastating surge in coronavirus cases in India has impacted vaccine supplies to the COVAX facility.
Among the global consequences of the situation in India, a global hub for vaccine production, is a severe reduction in vaccines available to COVAX.
Soaring domestic demand has meant that 140 million doses intended for distribution to low- and middle-income countries through the end of May cannot be accessed by COVAX. Another 50 million doses are likely to be missed in June, UNICEF Executive Director Henrietta Fore said in a statement.
A note to editors in the UNICEF statement said that shortfall numbers are based on delays related to shipments from the Serum Institute of India (SII) only. Other delays related to the original COVAX delivery schedule are expected to be made up by the end of June.
There is currently no timetable to resolve SII-related delays, the note said.
UNICEF said the COVAX facility will deliver its 65 millionth dose in the coming days when it should have been at least its 170 millionth.
By the time G7 leaders gather in the UK next month, and as a deadly second wave of COVID-19 will likely continue to sweep across India and many of its South Asian neighbours, the shortfall will be near 190 million doses.
The UNICEF Executive Director said in addition to vaccine nationalism, limited production capacity and lack of funding is the reason why the roll-out of COVID vaccines is so behind schedule.
While expressing concern over the surge in coronavirus cases in India, Fore said the UN has issued repeated warnings of the risks of "letting down our guard and leaving low- and middle-income countries without equitable access to vaccines, diagnostics and therapeutics.
We are concerned that the deadly spike in India is a precursor to what will happen if those warnings remain unheeded. While the situation in India is tragic, it is not unique.
Cases are exploding and health systems are struggling in countries near like Nepal, Sri Lanka and Maldives and far, like Argentina and Brazil, Fore said, warning that the cost for children and families will be incalculable.
The longer the virus continues to spread unchecked, the higher the risk of more deadly or contagious variants emerging, she said, adding that the clearest pathway out of this pandemic is a global, equitable distribution of vaccines, diagnostics and therapeutics.
While COVAX -- led by the WHO, Vaccine Alliance Gavi and Coalition for Epidemic Preparedness Innovations with UNICEF as implementing partner -- represents such a pathway, Fore voiced her concern that COVAX is undersupplied.
Earlier this month, SII CEO Adar Poonawalla said it was not possible to ramp up production overnight since vaccine manufacturing is a specialised process. The SII has received total orders of over 26 crore doses from the Government of India, of which more than 15 crore doses have been supplied.
In a tweet last week, Poonawalla said that the SII is doing our best to ramp up production & launch new vaccines on priority for India.
Fore cited new data analysis provided by life sciences research facility Airfinity that indicates that G7 nations and Team Europe' group of European Union Member States could donate around 153 million vaccine doses if they shared just 20 per cent of their available supply over June, July and August.
The WHO chief said Pfizer has committed to providing 40 million doses of vaccines with COVAX this year, but the majority of these would be in the second half of 2021.
Moderna also has signed a deal for 500 million doses with COVAX, but the majority has been promised only for 2022.
As per the pact which included funding to support manufacturing increase, the SII is contracted to provide COVAX with the SII-licensed and manufactured AstraZeneca (AZ)-Oxford vaccine (known as COVISHIELD) to 64 lower-income economies participating in the Gavi COVAX AMC (including India), alongside its commitments to the Government of India, the WHO had said.
Last year, it was announced that the collaboration among SII, Gavi and the Gates Foundation would accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines for low- and middle-income countries in 2021.
India's COVID-19 death toll on Tuesday climbed to 2,78,719 with a record 4,329 fresh fatalities, while the single day rise in cases stood at 2.63 lakh, the lowest in 28 days, according to the Union Health Ministry data.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.